Key result
In patients with CKD, current smoking was associated with a higher prevalence of coronary artery calcification compared with never smoking (PR 1.25; 95% CI 1.10-1.42).
Why the study?
Smoking is linked to vascular calcification and cardiovascular risk, but the relationship of smoking dose and cessation with coronary artery calcification in CKD needed investigation.
Does smoking cessation reduce the prevalence and progression of coronary artery calcification in patients with CKD compared to current smoking?
Cohort (n=1,914)
Yes
Does smoking cessation reduce the prevalence and progression of coronary artery calcification in patients with CKD compared to current smoking?
Relative Risk: 1.25 (95% CI 1.1–1.42)
In patients with CKD, smoking cessation is associated with a lower risk of prevalent coronary artery calcification and its progression compared to current smoking.
May support smoking cessation counseling in CKD; leaves open causal effects on CAC progression pending prospective validation.
BACKGROUND AND OBJECTIVES: Smoking is associated with vascular calcification and a higher risk of cardiovascular disease. In this study, we investigated the association of smoking dose and cessation with coronary artery calcification (CAC) in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From a nationwide, prospective cohort of Korean patients with CKD, 1914 participants were included. Prevalent CAC was defined as an Agatston score >0, using computed tomography. CAC progression was defined as ≥30%/yr increase in Agatston score at the 4-year follow-up examination in patients with baseline CAC. RESULTS: Prevalent CAC was observed in 952 (50%) patients. Compared with never smokers, former smokers had a similar prevalence ratio for CAC, but current smokers had a 1.25-fold higher prevalence ratio (95% confidence interval [95% CI], 1.10 to 1.42). Among former smokers, a lower smoking load of <10 pack-years (prevalence ratio, 0.77; 95% CI, 0.65 to 0.90) and longer duration of smoking cessation (prevalence ratio for 10 to <20 years, 0.85; 95% CI, 0.73 to 0.98: prevalence ratio for ≥20 years, 0.83; 95% CI, 0.73 to 0.96) were associated with lower risk of prevalent CAC compared with current smoking. The prevalence ratios did not differ between never smoking and long-term cessation. However, short-term cessation with heavy smoking load was associated with a higher risk of prevalent CAC (prevalence ratio, 1.21; 95% CI, 1.03 to 1.40) compared with never smoking. CAC progression was observed in 111 (33%) patients with baseline CAC. Compared with never smokers, former smokers showed a similar risk of CAC progression, but current smokers had a higher risk (relative risk, 1.92; 95% CI, 1.30 to 2.86). CONCLUSIONS: In CKD, former smoking with a lower smoking load and long-term cessation were associated with a lower risk of prevalent CAC than current smoking. CAC progression was more pronounced in current smokers.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2021) conducted a cohort in Chronic Kidney Disease (CKD) (n=1,914). Current smoking vs. Never smoking was evaluated on Prevalent coronary artery calcification (Agatston score >0) (PR 1.25, 95% CI 1.10-1.42). In patients with CKD, current smoking was associated with a higher prevalence of coronary artery calcification compared with never smoking (PR 1.25; 95% CI 1.10-1.42).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: